Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Finkler

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Mount Sinai Journal of Medicine, New York|March 1, 1978
Chalones: a mini-reviewN Finkler, P Acker
The Mount Sinai Journal of Medicine, New York|July 1, 1982
Studies in pancreatic function VII. Diabetes, exocrine pancreatic function and pancreatic diseaseD A Dreiling, H Grateron, N Finkler, et al.
European Heart Journal|August 15, 2002
Defining the optimum upper heart rate limit during exercise: a study in pacemaker patients with heart failureM Kindermann, B Schwaab, N Finkler, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 22, 2005
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter studyA N Gordon, N Finkler, R P Edwards, et al.
European Journal of Cancer (Oxford, England : 1990)|June 12, 2009
Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancerI Vergote, N Finkler, J del Campo, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Mount Sinai Journal of Medicine, New York|March 1, 1978
Chalones: a mini-reviewN Finkler, P Acker
The Mount Sinai Journal of Medicine, New York|July 1, 1982
Studies in pancreatic function VII. Diabetes, exocrine pancreatic function and pancreatic diseaseD A Dreiling, H Grateron, N Finkler, et al.
European Heart Journal|August 15, 2002
Defining the optimum upper heart rate limit during exercise: a study in pacemaker patients with heart failureM Kindermann, B Schwaab, N Finkler, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 22, 2005
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter studyA N Gordon, N Finkler, R P Edwards, et al.
European Journal of Cancer (Oxford, England : 1990)|June 12, 2009
Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancerI Vergote, N Finkler, J del Campo, et al.
Pageof 1